Home Protein Tyrosine Kinase Tyro3

Tyro3

Tyro3 Products

  • All (10)
  • Tyro3 Inhibitors (8)
  • Tyro3 Antibodie (1)
  • New Tyro3 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1561 BMS-777607 BMS-777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.
Cell Rep, 2025, 44(8):116096
Exp Ther Med, 2025, 29(6):110
Cancer Lett, 2024, 587:216692
BMS-777607 Customer Review
S7638 LDC1267 LDC1267 is a highly selective TAM kinase inhibitor with IC50 of <5 nM, 8 nM, and 29 nM for Mer, Tyro3, and Axl, respectively. Displays lower activity against Met, Aurora B, Lck, Src, and CDK8.
Cell Metab, 2021, S1550-4131(21)00326-0
J Clin Invest, 2021, 131(8)e139434 139434
J Clin Invest, 2021, 131(8)139434
LDC1267 Customer Review
S7576 UNC2025 HCl UNC2025 HCl is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3.
Immunity, 2023, 56(8):1778-1793.e10
Cell Rep, 2022, 38(13):110600
Cancers (Basel), 2021, 13(23)6072
S9662 UNC2025 UNC2025 is a potent and orally active dual inhibitor of FLT3 and MER with IC50 of 0.35 nM and 0.46 nM, respectively. UNC2025 also inhibits AXL, TRKA, TRKC, QIK, TYRO3, SLK, NuaK1, Kit (c-Kit) and Met (c-Met) with IC50 of 1.65 nM, 1.67 nM, 4.38 nM, 5.75 nM, 5.83 nM, 6.14 nM, 7.97 nM, 8.18 nM and 364 nM, respectively.
iScience, 2024, 27(7):110226
Commun Biol, 2023, 6(1):916
Commun Biol, 2023, 6(1):916
S8570 CEP-40783 (RXDX-106) CEP-40783 (RXDX-106) is an orally-available, potent and selective TAM(TYRO3, AXL, MER)/Met (c-Met) inhibitor displaying low nanomolar biochemical activity and slow (T1/2 >120 min) inhibitor off-rate in peptide phosphorylation assays and in vitro kinase binding assays, respectively.
UNIVERSITY OF CALIFORNIA, 2023,
bioRxiv, 2023, 2023.10.20.563266
Mol Cancer Res, 2022, 20(4):542-555
S7325 UNC2881 UNC2881 is a specific Mer tyrosine kinase inhibitor with IC50 of 4.3 nM, about 83- and 58-fold selectivity over Axl and Tyro3, respectively.
Cell Rep, 2020, 30(11):3671-3681
Front Immunol, 2019, 10:2647
F0612 Anti-Tyro3 Rabbit Antibody [E18F19]
E5942New UNC9426 UNC9426 (compound 12) is a potent and orally bioavailable inhibitor of TYRO3 with an IC50 of 2.1 nM. It reduces platelet aggregation without prolonging bleeding time and effectively suppresses TYRO3-mediated signalling pathways in tumor cells and macrophages.
S0071 RU-301 RU-301 is a pan-TAM receptor (Axl, Tyro3 and Mertk) inhibitor that blocks the Axl receptor dimerization site with Kd of 12 μM and IC50 of 10 μM, respectively.
A2698 Anti-TYRO3 (ELB031) Anti-TYRO3 (ELB031) is a monoclonal antibody that targets TYRO3 and MERTK.
S1561 BMS-777607 BMS-777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.
Cell Rep, 2025, 44(8):116096
Exp Ther Med, 2025, 29(6):110
Cancer Lett, 2024, 587:216692
 BMS-777607 Customer Review
S7638 LDC1267 LDC1267 is a highly selective TAM kinase inhibitor with IC50 of <5 nM, 8 nM, and 29 nM for Mer, Tyro3, and Axl, respectively. Displays lower activity against Met, Aurora B, Lck, Src, and CDK8.
Cell Metab, 2021, S1550-4131(21)00326-0
J Clin Invest, 2021, 131(8)e139434 139434
J Clin Invest, 2021, 131(8)139434
 LDC1267 Customer Review
S7576 UNC2025 HCl UNC2025 HCl is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3.
Immunity, 2023, 56(8):1778-1793.e10
Cell Rep, 2022, 38(13):110600
Cancers (Basel), 2021, 13(23)6072
S9662 UNC2025 UNC2025 is a potent and orally active dual inhibitor of FLT3 and MER with IC50 of 0.35 nM and 0.46 nM, respectively. UNC2025 also inhibits AXL, TRKA, TRKC, QIK, TYRO3, SLK, NuaK1, Kit (c-Kit) and Met (c-Met) with IC50 of 1.65 nM, 1.67 nM, 4.38 nM, 5.75 nM, 5.83 nM, 6.14 nM, 7.97 nM, 8.18 nM and 364 nM, respectively.
iScience, 2024, 27(7):110226
Commun Biol, 2023, 6(1):916
Commun Biol, 2023, 6(1):916
S8570 CEP-40783 (RXDX-106) CEP-40783 (RXDX-106) is an orally-available, potent and selective TAM(TYRO3, AXL, MER)/Met (c-Met) inhibitor displaying low nanomolar biochemical activity and slow (T1/2 >120 min) inhibitor off-rate in peptide phosphorylation assays and in vitro kinase binding assays, respectively.
UNIVERSITY OF CALIFORNIA, 2023,
bioRxiv, 2023, 2023.10.20.563266
Mol Cancer Res, 2022, 20(4):542-555
S7325 UNC2881 UNC2881 is a specific Mer tyrosine kinase inhibitor with IC50 of 4.3 nM, about 83- and 58-fold selectivity over Axl and Tyro3, respectively.
Cell Rep, 2020, 30(11):3671-3681
Front Immunol, 2019, 10:2647
E5942New UNC9426 UNC9426 (compound 12) is a potent and orally bioavailable inhibitor of TYRO3 with an IC50 of 2.1 nM. It reduces platelet aggregation without prolonging bleeding time and effectively suppresses TYRO3-mediated signalling pathways in tumor cells and macrophages.
S0071 RU-301 RU-301 is a pan-TAM receptor (Axl, Tyro3 and Mertk) inhibitor that blocks the Axl receptor dimerization site with Kd of 12 μM and IC50 of 10 μM, respectively.
A2698 Anti-TYRO3 (ELB031) Anti-TYRO3 (ELB031) is a monoclonal antibody that targets TYRO3 and MERTK.
E5942New UNC9426 UNC9426 (compound 12) is a potent and orally bioavailable inhibitor of TYRO3 with an IC50 of 2.1 nM. It reduces platelet aggregation without prolonging bleeding time and effectively suppresses TYRO3-mediated signalling pathways in tumor cells and macrophages.

Choose Selective Tyro3 Inhibitors

Tags: Tyro3 inhibitor|Tyro3 agonist|Tyro3 activator|Tyro3 inducer|Tyro3 antagonist|Tyro3 signaling pathway|Tyro3 assay kit